Loading company…
Seoul biotechnology company developing oncology drugs guided by predictive biomarkers, working with Seoul Asan Medical Center.
Founded in 2016 and headquartered in Seoul, South Korea, WellmarkerBio Co., Ltd. develops oncology drugs that use predictive biomarkers to assess therapeutic efficacy before treatment. It collaborates with Seoul Asan Medical Center and targets markets in South Korea and the United States. In 2023 it reported revenue of KRW 64,957.3 mn and EBITDA of KRW -6,464,469.1 mn. It raised KRW 14 billion in Series C funding in August 2021 from investors including Magellan Technology Investment and GeneN Investment Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in